Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ketek Superiority Trials May Hold Key To Sales After Safety Relabeling

Executive Summary

Sanofi-Aventis recently conducted superiority trials for its antibiotic Ketek, and the results could determine whether the drug bounces back from an FDA decision to withdraw two indications from the drug's label

You may also be interested in...



Antibiotic Trial Standards To Be Revised By FDA Under Congressional Mandate

Manufacturers of antibiotics need to get involved as FDA writes clinical trial guidance for antibiotic drugs, according to Bruce Burlington, an independent consultant and former Wyeth VP

Antibiotic Trial Standards To Be Revised By FDA Under Congressional Mandate

Manufacturers of antibiotics need to get involved as FDA writes clinical trial guidance for antibiotic drugs, according to Bruce Burlington, an independent consultant and former Wyeth VP

PDUFA Public Forum Previews Hill Debate; Safety, Critical Path Emphasized

With the Prescription Drug User Fee Act moving towards reauthorization, a public forum on Feb. 16 hinted at how that debate may play out on Capitol Hill. At the meeting sponsored by FDA, outside groups voiced concerns about the agency's proposal for the PDUFA program and made their case for how FDA should organize and spend requested funding

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel